Clinical Trials Directory

Trials / Completed

CompletedNCT01472822

Efficacy of Omija (Schisandra Chinensis) Extract in Subjects With Knee Osteoarthritis

Efficacy and Safety of Omija Extract on Gonarthritis

Status
Completed
Phase
Phase 2 / Phase 3
Study type
Interventional
Enrollment
60 (actual)
Sponsor
Chonbuk National University Hospital · Academic / Other
Sex
All
Age
30 Years – 70 Years
Healthy volunteers
Accepted

Summary

Knee osteoarthritis (KO) is a common arthropathy and a leading cause of disability in elderly adults. Schizandra chinensis(Omija) has been known to have five predominant tastes: salty, sweet, sour, astringent, and bitter. It has also been shown to have various effects on the anti-inflammatory, cardiovascular system, gastrointestinal system, central nervous system, endocrine system, and stress protect. Therefore, this study is designed to evaluate the efficacy and safety on KO of Omija extract.

Detailed description

In the present study, the investigators will assess the efficacy and safety of the formulation of Omija extract(1,200 mg administered twice a day) on the symptoms of knee osteoarthritis (KO) during a 12-week treatment course. In a randomized, double-blind placebo-controlled trial, subjects will be randomly assign to receive oral omija treatment group(n=30) or placebo group(n=30). The primary efficacy outcome measure will be score change in the WOMAC(Western Ontario and McMaster University Osteoarthritis Index) after 12-weeks. Secondary parameters will be included the Lysholm index score, hs-CRP, osteocalcin(OSC), and deoxypyridinoline(DPYR).

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTOmija extract.Omija extract 1.2g/day for 12weeks
DIETARY_SUPPLEMENTPlaceboPlacebo 1.2g/day for 12weeks

Timeline

Start date
2011-03-01
Primary completion
2011-06-01
Completion
2011-12-01
First posted
2011-11-17
Last updated
2013-02-04
Results posted
2013-02-04

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT01472822. Inclusion in this directory is not an endorsement.